BIODESIX INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
Balance Sheets
(in thousands, except share data)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $18,987 | $26,245 |
| Accounts receivable, net of allowance for credit losses of $62 and $481 | 9,036 | 8,603 |
| Other current assets | 4,495 | 4,636 |
| Total current assets | 32,518 | 39,484 |
| Non‑current assets | ||
| Property and equipment, net | 24,817 | 27,828 |
| Intangible assets, net | 3,883 | 5,874 |
| Operating lease right-of-use assets | 2,997 | 1,767 |
| Goodwill | 15,031 | 15,031 |
| Other long-term assets | 8,230 | 7,260 |
| Total non‑current assets | 54,958 | 57,760 |
| Total assets | $87,476 | $97,244 |
| Liabilities and Stockholders' (Deficit) Equity | ||
| Current liabilities | ||
| Accounts payable | $3,080 | $2,194 |
| Accrued liabilities | 11,033 | 10,064 |
| Deferred revenue | 961 | 678 |
| Current portion of operating lease liabilities | 1,364 | 719 |
| Current portion of notes payable | 6 | 21 |
| Other current liabilities | 992 | 641 |
| Total current liabilities | 17,436 | 14,317 |
| Non‑current liabilities | ||
| Long‑term notes payable, net of current portion | 47,445 | 36,408 |
| Long-term operating lease liabilities | 24,039 | 24,828 |
| Other long-term liabilities | 1,021 | 815 |
| Total non‑current liabilities | 72,505 | 62,051 |
| Total liabilities | 89,941 | 76,368 |
| Commitments and contingencies | ||
| Stockholders’ (deficit) equity | ||
| Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2025 and 2024) issued and outstanding | — | — |
| Common stock, $0.001 par value, 200,000,000 authorized; 8,253,053 (2025) and 7,274,578 (2024) shares issued and outstanding(a) | 8 | 7 |
| Additional paid‑in capital(a) | 495,289 | 483,366 |
| Accumulated deficit | (497,762) | (462,497) |
| Total stockholders’ (deficit) equity | (2,465) | 20,876 |
| Total liabilities and stockholders’ (deficit) equity | $87,476 | $97,244 |
(a)All share information, Common stock balances, and Additional paid-in capital balances have been adjusted to reflect the 1-for-20 reverse stock split effective September 15, 2025. See Note 2 –Summary of Significant Accounting Policies for further details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.